Medafor Matters (Details) (USD $) Share data in Millions, unless otherwise specified	3 Months Ended		9 Months Ended			3 Months Ended	0 Months Ended		3 Months Ended		6 Months Ended	42 Months Ended	3 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2013 Scenario, Forecast [Member]	Oct. 21, 2013 Medafor Inc. [Member]	Sep. 30, 2013 Medafor Inc. [Member]	Sep. 30, 2012 Medafor Inc. [Member]	Dec. 31, 2012 Medafor Inc. [Member]	Dec. 31, 2014 C.R. Bard, Inc. [Member] Scenario, Forecast [Member]	Dec. 31, 2017 C.R. Bard, Inc. [Member] Scenario, Forecast [Member]	Jun. 30, 2012 Medafor Settlement [Member]
Subsidiary or Equity Method Investee [Line Items]
Shares purchased under stock purchase agreement								2.4		2.4
Investment in equity securities	$ 5,908,000		$ 5,908,000		$ 5,908,000			$ 2,600,000		$ 2,600,000
Value of Medafor derivative										0
Initial payment received from C.R. Bard for acquisition of outstanding shares of common stock							15,400,000
Outstanding shares of common stock acquired by C.R. Bard								2.4
Initial gain on sale of outstanding shares of common stock						12,700,000
Additional payments that could be received												8,400,000
Approximate amount that could be received from first possible additional payment											575,000
Proceeds from legal settlement									3,500,000
Gain recorded as a reduction in general, administrative, and marketing expenses	16,532,000	16,533,000	51,441,000	48,374,000									4,700,000
Receivable for settlement payments	20,663,000		20,663,000		16,520,000
Discharged reduction in accounts payable pursuant to settlement agreement													$ 1,200,000